Compare ABCB & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABCB | ORKA |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.6B |
| IPO Year | 2010 | 1997 |
| Metric | ABCB | ORKA |
|---|---|---|
| Price | $80.13 | $79.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $94.17 | ★ $155.00 |
| AVG Volume (30 Days) | 409.3K | ★ 865.0K |
| Earning Date | 10-22-2026 | 11-11-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ 15.61 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.52 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $33.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $68.80 | $20.25 |
| 52 Week High | $93.22 | $115.52 |
| Indicator | ABCB | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 32.05 |
| Support Level | $73.43 | $54.31 |
| Resistance Level | $83.83 | $97.45 |
| Average True Range (ATR) | 1.47 | 4.42 |
| MACD | -0.15 | -0.87 |
| Stochastic Oscillator | 27.80 | 9.95 |
Ameris Bancorp is a bank holding company that operates through Ameris Bank, its subsidiary. The company operates branches in Georgia, Alabama, Florida, and South Carolina. It offers traditional banking services such as business banking, personal banking, checking, savings, mobile banking, and others. The bank is organized into four segments: the Banking Division, the Retail Mortgage Division, the Warehouse Lending Division and the Premium Finance Division. The company generates majority of its revenue from the banking division. The company intends to acquire banks in its geographic region to increase its market share and expand beyond its current market.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.